- Home
- AXR vs RAPT Comparison
AXR vs RAPT Comparison
Compare AXR & RAPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AXR
- RAPT
- Stock Information
- Founded
- AXR 1961
- RAPT 2015
- Country
- AXR United States
- RAPT United States
- Employees
- AXR N/A
- RAPT N/A
- Industry
- AXR Homebuilding
- RAPT Biotechnology: Pharmaceutical Preparations
- Sector
- AXR Real Estate
- RAPT Health Care
- Exchange
- AXR Nasdaq
- RAPT Nasdaq
- Market Cap
- AXR 114.8M
- RAPT 194.2M
- IPO Year
- AXR N/A
- RAPT 2019
- Fundamental
- Price
- AXR $21.55
- RAPT $11.74
- Analyst Decision
- AXR
- RAPT Buy
- Analyst Count
- AXR 0
- RAPT 5
- Target Price
- AXR N/A
- RAPT $33.60
- AVG Volume (30 Days)
- AXR 9.5K
- RAPT 105.9K
- Earning Date
- AXR 09-12-2025
- RAPT 08-07-2025
- Dividend Yield
- AXR N/A
- RAPT N/A
- EPS Growth
- AXR 89.60
- RAPT N/A
- EPS
- AXR 2.37
- RAPT N/A
- Revenue
- AXR $49,694,000.00
- RAPT N/A
- Revenue This Year
- AXR $124,160.48
- RAPT N/A
- Revenue Next Year
- AXR $8.16
- RAPT N/A
- P/E Ratio
- AXR $9.09
- RAPT N/A
- Revenue Growth
- AXR N/A
- RAPT N/A
- 52 Week Low
- AXR $17.60
- RAPT $5.67
- 52 Week High
- AXR $39.68
- RAPT $26.56
- Technical
- Relative Strength Index (RSI)
- AXR 43.53
- RAPT 58.44
- Support Level
- AXR $21.94
- RAPT $10.20
- Resistance Level
- AXR $22.65
- RAPT $13.50
- Average True Range (ATR)
- AXR 0.64
- RAPT 1.01
- MACD
- AXR -0.09
- RAPT -0.05
- Stochastic Oscillator
- AXR 2.82
- RAPT 77.46
About AXR AMREP Corporation
Amrep Corp through its subsidiaries is engaged in the Real estate business. Its activities include land sales and lease activities, which involve obtaining approvals and selling both developed and undeveloped lots to homebuilders, commercial users, and others, as well as investments in commercial and investment properties. The Company accounts for land sales, home sales, and other revenues. Its operating segments include Land development and Homebuilding. The firm generates a majority of its revenue from the Land development segment. Geographically, all the activities are carried out throughout the United States.
About RAPT RAPT Therapeutics Inc.
RAPT Therapeutics Inc is a clinical-stage immunology-based biopharmaceutical company. It is focused on discovering, developing, and commercializing oral small-molecule therapies for patients with some unmet needs in oncology and inflammatory diseases. The company pipeline products include FLX475, designed to selectively inhibit the migration of immunosuppressive regulatory T cells into tumors; and RPT193, designed to selectively inhibit the migration of type 2 T helper cells into inflamed tissues.